Market Overview

There Could Be 109% Upside In uniQure As Company Advances Gene Therapy Into Clinical Trials

Share:
There Could Be 109% Upside In uniQure As Company Advances Gene Therapy Into Clinical Trials
Related QURE
The Daily Biotech Pulse: Biohaven In-Licenses Drug, Retrophin's Debt Offering, ProQR And Bluebird Report Positive Trial Results
The Daily Biotech Pulse: Verastem Gets New CFO, Mesoblast Earnings, Vertex's Precision Medicine Collaboration

Following its meeting with the FDA and the EMA, Uniqure NV (NASDAQ: QURE) announced it would expeditiously advance its adeno-associated virus, or AAV-based gene therapy, AMT-061 into pivotal trials in severe and moderately severe hemophilia B.

Reacting to the announcement, Chardan maintains its Buy rating on uniQure and raised its price target to $35, attributing the revision to Hemophilia B and the return of tangible pipeline value. The price target suggests a 109 percent gain from $16.75 at which the shares opened today.

At last check, shares of uniQure were skyrocketing 25.33 percent to $19.

Analyst Gbola Amusa said AMT-061 will use AAV5 and the FIX-Padua mutant, which provides six to nine times more FIX activity than the naturally-occurring FIX. The analyst also noted that the company announced it had obtained exclusive use of a patent family that broadly covers the FIX-Padua variant.

FIX is a serine proteases of the coagulation system, the deficiency of which causes hemophilia B.

See also: Attention Biotech Investors, Here's Your PDUFA Primer For October

Amusa pointed out that AMT-061 will be included under existing Breakthrough Therapy and PRIME designations under the existing IND for AMT-060, which was shelved in favor of AMT-061.

The company will conduct a short dose-confirmatory study in the third quarter, which will run for six weeks, with the pivotal trial also set to start in 2018. Additional pre-clinical data for AMT-061 will be announced at the American Society of Hematology conference taking place between Dec. 9 and 12 in Atlanta, Georgia.

tipranks.png

Chardan believes uniQure can achieve hemophilia B segment leadership in vector gene therapy, with the view premised on the company's leading manufacturing capabilities, and its utilization of the AAV5 capsid and the FIX-Padua variant.

The firm said the company's product likely enables broader use in hemophilia B than other vector gene therapy. Additionally, the firm said Padua should enable best-in-class efficacy for AMT-061, similar to that for Spark Therapeutics Inc (NASDAQ: ONCE)'s SPK-9001.

"UniQure is confident that AMT-061 could lead to mean FIX activity of ~30-50% of normal, which we think is consistent," the firm added.

Latest Ratings for QURE

DateFirmActionFromTo
Jul 2018Cantor FitzgeraldInitiates Coverage OnOverweight
Jun 2018B. Riley FBRInitiates Coverage OnBuy
May 2018SunTrust Robinson HumphreyInitiates Coverage OnBuy

View More Analyst Ratings for QURE
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Long Ideas News Price Target Reiteration Analyst Ratings Movers Best of Benzinga

 

Related Articles (QURE + ONCE)

View Comments and Join the Discussion!

Athenahealth Q3 Just A Little Worse Than Expected, Things Could Get Better From Here

Upcoming Earnings: Heavy-Equipment Maker Caterpillar And Pharma Giant Eli Lilly Report On Tuesday